0001493152-24-020551.txt : 20240520 0001493152-24-020551.hdr.sgml : 20240520 20240520092520 ACCESSION NUMBER: 0001493152-24-020551 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20240520 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240520 DATE AS OF CHANGE: 20240520 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Sonnet BioTherapeutics Holdings, Inc. CENTRAL INDEX KEY: 0001106838 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 522102141 STATE OF INCORPORATION: DE FISCAL YEAR END: 0930 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35570 FILM NUMBER: 24962741 BUSINESS ADDRESS: STREET 1: 100 OVERLOOK CENTER STREET 2: SUITE 102 CITY: PRINCETON STATE: NJ ZIP: 08540 BUSINESS PHONE: 609-375-2227 MAIL ADDRESS: STREET 1: 100 OVERLOOK CENTER STREET 2: SUITE 102 CITY: PRINCETON STATE: NJ ZIP: 08540 FORMER COMPANY: FORMER CONFORMED NAME: Chanticleer Holdings, Inc. DATE OF NAME CHANGE: 20050510 FORMER COMPANY: FORMER CONFORMED NAME: TULVINE SYSTEMS INC DATE OF NAME CHANGE: 20000214 8-K 1 form8-k.htm
false 0001106838 0001106838 2024-05-20 2024-05-20 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): May 20, 2024

 

SONNET BIOTHERAPEUTICS HOLDINGS, INC.

 

(Exact name of registrant as specified in its charter)

 

Delaware   001-35570   20-2932652

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

 

100 Overlook Center, Suite 102

Princeton, New Jersey

   08540
(Address of principal executive office)   (Zip Code)

 

Registrant’s telephone number, including area code: (609) 375-2227

 

Not Applicable

(Former name or former address, if changed since last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)  

Name of each exchange on which registered

Common Stock, $0.0001 par value per share   SONN   The Nasdaq Capital Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 7.01 Regulation FD.

 

On May 20, 2024, Sonnet BioTherapeutics Holdings, Inc. (the “Company”) issued a press release announcing updated clinical data for its candidate immunotherapeutic recombinant drug, SON-1010, as monotherapy or combined with atezolizumab (in collaboration with Genentech, a member of the Roche Group), and an increase of the target dose of SON-1010 during dose escalation in both of the Company’s current Phase 1 clinical trials. A copy of the press release is attached hereto as Exhibit 99.1.

 

The information in this Current Report on Form 8-K under Item 7.01, including the information contained in Exhibit 99.1, is being furnished to the Securities and Exchange Commission (the “SEC”), and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by a specific reference in such filing.

 

Item 8.01 Other Events.

 

On May 20, 2024, the Company announced updated clinical data for SON-1010 as a monotherapy and combined with atezolizumab (Tecentriq®), an anti-PD-L1, and an increase in the target dose of SON-1010 during dose escalation in both of the Company’s current Phase 1 clinical trials. The Company’s SON-1010 studies have together enrolled 61 subjects, to date, as dose escalation continues in SB101 and SB221 at higher levels. Patients have received up to 25 cycles of SON-1010 as monotherapy and 10 cycles of SON-1010 with atezolizumab without dose-limiting toxicity at any dose level. The Company’s cytokine data revealed about 10-fold extended half-life for SON-1010 compared with rhIL-12 that induces prolonged and controlled IFNγ responses, with no evidence of cytokine release syndrome at any dose.

 

The safety of SON-1010 dosing has been formally reviewed in two current Phase 1 clinical trials and the Company is now increasing the target dose of SON-1010 during dose escalation. SON-1010 is a proprietary version of recombinant human interleukin-12 (rhIL-12), configured using the Company’s Fully Human Albumin Binding (FHAB®) platform, which extends the half-life and activity of the IL-12 component due to binding native albumin in the serum and targets the tumor microenvironment (TME) by strongly binding gp60 and Secreted Protein Acidic and Rich in Cysteine (SPARC). SB101 is a Phase 1 multiple-ascending dose (MAD) trial in adult patients with advanced solid tumors (NCT05352750) that commenced in Q2 2022 and is currently enrolling the sixth dose cohort. SB221 is a Phase 1b/2a dose-escalation and proof-of-concept study of the combination of SON-1010 with atezolizumab (in collaboration with Genentech, a member of the Roche Group), in a study focused on platinum-resistant ovarian cancer (PROC) (NCT05756907) that started in Q4 2023, now enrolling the fourth dose cohort. In addition, SON-1010 was studied in SB102, which was a Phase 1 single-ascending dose (SAD) trial in healthy volunteers (NCT05408572) that started in Q3 2022, the results were recently published (Kenney, et al, Frontiers in Immunology, 2024).

 

Safety in both of the active cancer trials has been reviewed by their respective Safety Review Committees at each step during dose escalation. Both trials use a ‘desensitizing’ first dose to take advantage of the known tachyphylaxis with rhIL-12, which minimizes toxicity and allows higher maintenance doses. No dose-limiting toxicities or related serious adverse events have occurred to date. The safety and toxicity profile that has developed is typical for a Phase 1 oncology trial, with the majority of adverse events (AEs) being reported as mild. All have been transient, with no evidence of cytokine release syndrome. Of the 25 cancer patients dosed to date and evaluable for follow-up at this latest cutoff, 15 (60%) had stable disease at their first follow-up scan, 8 of whom were progressing at study entry. At four months follow-up, 8 of 23 evaluable patients remained stable at the second CT scan, suggesting clinical benefit of SON-1010 in 35% of the patients.

 

One patient with progressive endometrial sarcoma receiving SON-1010 monotherapy in SB101 had stable disease (SD) for almost 2 years before progressing – her ascites had resolved and tumors had shrunk at one point but she never reached a partial response (PR) by Response Evaluation Criteria in Solid Tumors (RECIST) rules. Cytokine analysis following each dose in that study revealed controlled and prolonged induction of interferon gamma (IFNγ) that peaked at 24 to 48 hours and returned to baseline within 2 to 4 weeks. A small increase in IL-10 was observed with each dose as expected in response to IFNγ. There was either a minimal or no signal for IL-1β, IL-6, IL-8, and TNFα, and there was no indication of any potential for cytokine release syndrome (CRS) at these doses. One patient in Part 1 of SB221 with uterine sarcomas received 8 cycles of the SON-1010/atezolizumab combination therapy every 3 weeks before progressing; another two have received 8 and 10 cycles, respectively, and are continuing on the study. The stable AE profiles despite dose escalation led the Company to reevaluate the target dose, so the Company has added groups in both studies to evaluate 1200 ng/kg SON-1010 as a maintenance dose (the molar equivalent of 800 ng/kg rhIL-12). Finally, Part 2 of the SB221 combination study has been trimmed to remove the monotherapy arm.

 

 
 

 

Forward-Looking Statements

 

This Current Report on Form 8-K contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Exchange and Private Securities Litigation Reform Act, as amended, including those relating to the outcome of the Company’s clinical trials, the Company’s cash runway, the Company’s product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statements that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management’s current beliefs and assumptions.

 

These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential,” “predict,” “project,” “should,” “would” and similar expressions and the negatives of those terms. These statements relate to future events or the Company’s financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company’s filings with the SEC. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this Current Report. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit No.   Description
99.1   Press Release dated May 20, 2024
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  SONNET BIOTHERAPEUTICS HOLDINGS, INC.
   
Date: May 20, 2024 By:

/s/ Pankaj Mohan, Ph.D.

    Name: Pankaj Mohan, Ph.D.
    Title: Chief Executive Officer

 

 

 EX-99.1 2 ex99-1.htm

 

Exhibit 99.1

 

Sonnet BioTherapeutics Announces Updated Clinical Data for SON-1010 as Monotherapy or Combined with an anti-PD-L1, along with an Increase in the Dose-Escalation Target

 

  ● The SON-1010 studies have together enrolled 61 subjects, to date, as dose escalation continues in SB101 and SB221 at higher levels
  ● Patients have received up to 25 cycles of SON-1010 as monotherapy and 10 cycles of SON-1010 with atezolizumab (Tecentriq®) without dose-limiting toxicity at any dose level
  ● Cytokine data reveals about 10-fold extended half-life for SON-1010 compared with rhIL-12 that induces prolonged and controlled IFNγ responses, with no evidence of cytokine release syndrome at any dose
  ● Clinical benefit was seen at four months post-initiation of dosing in 35% of evaluable patients (8/23) with advanced solid tumors

 

PRINCETON, NJ / ACCESSWIRE / May 20, 2024 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (the “Company” or “Sonnet”), a clinical-stage company developing targeted immunotherapeutic drugs, announced today that the safety of SON-1010 dosing has been formally reviewed in both of the current Phase 1 clinical trials and the Company is now increasing the target dose of SON-1010 during dose escalation. SON-1010 is a proprietary version of recombinant human interleukin-12 (rhIL-12), configured using Sonnet’s Fully Human Albumin Binding (FHAB®) platform, which extends the half-life and activity of the IL-12 component due to binding native albumin in the serum and targets the tumor microenvironment (TME) by strongly binding gp60 and Secreted Protein Acidic and Rich in Cysteine (SPARC). SB101 is a Phase 1 multiple-ascending dose (MAD) trial in adult patients with advanced solid tumors (NCT05352750) that commenced in Q2 2022 and is currently enrolling the sixth dose cohort. SB221 is a Phase 1b/2a dose-escalation and proof-of-concept study of the combination of SON-1010 with atezolizumab (in collaboration with Genentech, a member of the Roche Group), in a study focused on platinum-resistant ovarian cancer (PROC) (NCT05756907) that started in Q4 2023, now enrolling the fourth dose cohort. In addition, SON-1010 was studied in SB102, which was a Phase 1 single-ascending dose (SAD) trial in healthy volunteers (NCT05408572) that started in Q3 2022; the results were recently published (Kenney, et al, Frontiers in Immunology, 2024).

 

Safety in both of the active cancer trials has been reviewed by their respective Safety Review Committees at each step during dose escalation. Both trials use a ‘desensitizing’ first dose to take advantage of the known tachyphylaxis with rhIL-12, which minimizes toxicity and allows higher maintenance doses. No dose-limiting toxicities or related serious adverse events have occurred to date. The safety and toxicity profile that has developed is typical for a Phase 1 oncology trial, with the majority of adverse events (AEs) being reported as mild. All have been transient, with no evidence of cytokine release syndrome. Of the 25 cancer patients dosed to date and evaluable for follow-up at this latest cutoff, 15 (60%) had stable disease at their first follow-up scan, 8 of whom were progressing at study entry. At four months follow-up, 8 of 23 evaluable patients remained stable at the second CT scan, suggesting clinical benefit of SON-1010 in 35% of the patients.

 

“We have now dosed 18 cancer patients at increasing SON-1010 drug levels in the SB101 study, completed dosing in 31 healthy volunteers in SB102, and are rapidly filling the dose-escalation cohorts with 12 subjects enrolled in the first four cohorts of the SB221 combination study,” said Richard Kenney, M.D., Sonnet’s Chief Medical Officer. “The overall safety and toxicity profile for SON-1010, primarily including local reactions, headache, myalgia, and fatigue, mimics the published experience with rhIL-12, which prompted us to raise the target dose to enhance potential efficacy. The SB102 study allowed us to generate clean data for the pharmacokinetic (PK) and pharmacodynamic (PD) analyses, enabling simulation of the effect of multiple doses with the help of a continual reassessment model of PK and PD. This modeling suggests target-mediated drug disposition (TMDD), which supports the mechanism of the FHAB being directed to tumor tissue. The combination of SON-1010 with atezolizumab may benefit from the ability of IL-12 to turn ‘cold’ tumors ‘hot’, which upregulates the amount of PD-L1 in the TME.”

 

 
 

 

One patient with progressive endometrial sarcoma receiving SON-1010 monotherapy in SB101 had stable disease (SD) for almost 2 years before progressing – her ascites had resolved and tumors had shrunk at one point but she never reached a partial response (PR) by Response Evaluation Criteria in Solid Tumors (RECIST) rules. Cytokine analysis following each dose in that study revealed controlled and prolonged induction of interferon gamma (IFNγ) that peaked at 24 to 48 hours and returned to baseline within 2 to 4 weeks. A small increase in IL-10 was observed with each dose as expected in response to IFNγ. There was either a minimal or no signal for IL-1β, IL-6, IL-8, and TNFα, and there was no indication of any potential for cytokine release syndrome (CRS) at these doses. One patient in Part 1 of SB221 with uterine sarcomas received 8 cycles of the SON-1010/atezolizumab combination therapy every 3 weeks before progressing; another two have received 8 and 10 cycles, respectively, and are continuing on the study. The stable AE profiles despite dose escalation led us to reevaluate the target dose, so the Company has added groups in both studies to evaluate 1200 ng/kg SON-1010 as a maintenance dose (the molar equivalent of 800 ng/kg rhIL-12). Finally, Part 2 of the SB221 combination study has been trimmed to remove the monotherapy arm.

 

“The findings to date in these two trials represent significant progress for the SON-1010 molecule”, said Robert Wenham, M.D., Chair, Department of GYN Oncology at Moffitt Cancer Center and the Lead Principal Investigator for SB221. “Multiple strategies to present IL-12 safely have been tried over the past two decades with little evidence of improved tolerability in humans, yet the preclinical models continue to suggest that induction of IFNγ in the TME can activate an effective anti-tumor response. This also results in the local induction of PD-L1. Adding a cohort to increase the target MTD of SON-1010, an extended PK molecule that is concentrated in the TME, is the right approach at this stage. This will provide a chance to study the safety of SON-1010 monotherapy in SB101, and then in combination with atezolizumab in SB221, along with the clinical effect of the combination on PROC in a limited set of subjects in the expansion cohort later this year. Defining the best dose for SON-1010 is required to allow a direct randomized comparison of the strategy with the standard of care therapy in Part 2.”

 

“We are very pleased with the data we are seeing at these higher dose levels of SON-1010, with safety and tolerability being well within expected levels, as well as displaying SON-1010 extended PK/PD, tumor targeting, and clinical activity during treatment,” said Pankaj Mohan, Ph.D., Sonnet Founder and Chief Executive Officer. “Research on rhIL-12 in humans has been hindered by toxicity for decades. We believe that the IL-12 component in SON-1010 is presented in a way that is safer, due to the longer half-life, and it is concentrated in the tumor, due to the recurrent binding of the FHAB-associated albumin to SPARC in the TME. It is important to note that many of these patients have been fighting their cancers for a very long time and have exhausted all approved treatment regimens available to them, so seeing tumor shrinkage at any dose is both difficult to achieve and encouraging for future results. We are excited to continue testing the impact of SON-1010 in combination with atezolizumab at these higher dose levels in patients with PROC, who represent a significant unmet medical need, and we expect to have a further update early next year.”

 

 
 

 

About SON-1010

 

SON-1010 is a candidate immunotherapeutic recombinant drug that links unmodified single-chain human IL-12 with the albumin-binding domain of the single-chain antibody fragment A10m3. This was selected to bind both at normal pH, as well as at the acidic pH typically found in the TME. The FHAB technology targets tumor and lymphatic tissue, providing a mechanism for dose sparing and an opportunity to improve the safety and efficacy profile of not only IL-12, but a variety of potent immunomodulators that can be added using the platform. Interleukin-12 can orchestrate a robust immune response to many cancers and pathogens. Given the types of proteins induced in the TME, such as the Secreted Protein and Rich in Cysteine (SPARC) and glycoprotein 60 (GP60), several types of cancer such as non-small cell lung cancer, melanoma, head and neck cancer, sarcoma, and some gynecological cancers are particularly relevant for this approach. SON-1010 is designed to deliver IL-12 to local tumor tissue, turning ‘cold’ tumors ‘hot’ by stimulating IFNγ, which activates innate and adaptive immune cell responses and increases the production of Programed Death Ligand 1 (PD-L1) on tumor cells.

 

About the SB101 Phase 1 Trial

 

This first-in-human study is primarily designed to evaluate the safety of multiple ascending doses of SON-1010 in cancer patients and will be conducted at several sites across the United States. While the optimal dose is unknown at this stage, the potential to target tumors, the extended PK mechanism and our preclinical data suggest the therapeutic dose may be lower compared to native human IL-12. The study, utilizing a standard 3+3 oncology design in at least five cohorts, should establish the MTD and the recommended Phase 2 dose (RP2D) using monthly subcutaneous injections of SON-1010. The primary endpoint explores the safety and tolerability of SON-1010, with key secondary endpoints intended to measure pharmacokinetics (PK), pharmacodynamics (PD), immunogenicity, and anti-tumor activity. This study will form the basis for potential combinations with other types of immunotherapies and the future development of bispecific candidates using the FHAB platform.

 

About the SB221 Phase 1b/2a Trial

 

SB221 is a global Phase 1b/2a multicenter, dose-escalation and randomized proof-of-concept study to assess the safety, tolerability, PK, PD, and efficacy of SON-1010 administered subcutaneously (SC), either alone or in combination with atezolizumab given intravenously (IV). The study is designed in Part 1 to rapidly establish the maximum tolerated dose (MTD) of the combination in patients with advanced solid tumors at the lower dose levels. The focus shifts to PROC at higher dose levels using small dose-escalation groups with expansion of the dataset at the recommended Phase 2 dose (RP2D). This would be followed in Part 2 by an assessment in patients with PROC of the potential for improved efficacy of the combination versus the standard of care. Both companies look forward to this collaboration as an opportunity to improve outcomes for patients with ovarian cancer.

 

About Sonnet BioTherapeutics Holdings, Inc.

 

Sonnet BioTherapeutics is an oncology-focused biotechnology company with a proprietary platform for innovating biologic drugs of single or bifunctional action. Known as FHAB (Fully Human Albumin Binding), the technology utilizes a fully human single chain antibody fragment (scFv) that binds to and “hitch-hikes” on human serum albumin (HSA) for transport to target tissues. Sonnet’s FHAB was designed to specifically target tumor and lymphatic tissue, with an improved therapeutic window for optimizing the safety and efficacy of immune modulating biologic drugs. FHAB is the foundation of a modular, plug-and-play construct for potentiating a range of large molecule therapeutic classes, including cytokines, peptides, antibodies, and vaccines.

 

Tecentriq® (atezolizumab) is a registered trademark of Genentech, a member of the Roche Group.

 

 
 

 

Forward-Looking Statements

 

This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the outcome of the Company’s clinical trials, the Company’s cash runway, the Company’s product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statements that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management’s current beliefs and assumptions.

 

These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential,” “predict,” “project,” “should,” “would” and similar expressions and the negatives of those terms. These statements relate to future events or the Company’s financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company’s filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

 

Sonnet BioTherapeutics Investor Contact

 

Jack Yauch

Solebury Strategic Communications

862-754-1024

jyauch@soleburystrat.com

 

SOURCE: Sonnet BioTherapeutics Holdings, Inc.

 

 

 EX-101.SCH 3 sonn-20240520.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 sonn-20240520_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 sonn-20240520_pre.xml XBRL PRESENTATION FILE XML 7 R1.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Cover
May 20, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date May 20, 2024
Entity File Number 001-35570
Entity Registrant Name SONNET BIOTHERAPEUTICS HOLDINGS, INC.
Entity Central Index Key 0001106838
Entity Tax Identification Number 20-2932652
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 100 Overlook Center
Entity Address, Address Line Two Suite 102
Entity Address, City or Town Princeton
Entity Address, State or Province NJ
Entity Address, Postal Zip Code 08540
City Area Code (609)
Local Phone Number 375-2227
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $0.0001 par value per share
Trading Symbol SONN
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( "E+M%@'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " I2[18P#.V:>\ K @ $0 &1O8U!R;W!S+V-O&ULS9+/ M3L,P#(=?!>7>.FTW#E'7"]-.("$Q"<0M2KPMHOFCQ*C=V].&K1."!^ 8^Y?/ MGR6W*@CE(SY''S"2P70WVMXEH<*&G8B" $CJA%:F42H.;\'BR2U) DSL @+D76M5D)%E.3C!:_5@@^?L<\PK0![M.@H0556P+IY M8CB/?0LWP PCC#9]%U OQ%S]$YL[P"[),9DE-0Q#.30Y-^U0P=O3XTM>MS N MD70*IU_)"#H'W+#KY-?F8;O?L:[F]:K@ZZ+F^ZH1]5I4J_?9]8??3=AZ;0[F M'QM?!;L6?MU%]P502P,$% @ *4NT6)E&UL[5I;<]HX%'[OK]!X9_9M"\8V@;:T$W-I=MNTF83M M3A^%$5B-;'EDD81_OTV23;J;/ 0LZ?O.14?GZ#AY\^XN8NB&B)3R M> +]O6N[!3+ MUES@6QHO(];JM-O=5H1I;*$81V1@?5XL:$#05%%:;U\@M.4?,_@5RU2-9:,! M$U=!)KF(M/+Y;,7\VMX^9<_I.ATR@6XP&U@@?\YOI^1.6HCA5,+$P&IG/U9K MQ]'22(""R7V4!;I)]J/3%0@R#3LZG5C.=GSVQ.V?C,K:=#1M&N#C\7@XMLO2 MBW A(5M>5 TR M6'!VULS2 Y9>*?IUE!K9';O=05SP6.XYB1'^QL4$UFG2&98T1G*=D 4. #?$ MT4Q0?*]!MHK@PI+27)#6SRFU4!H(FLB!]4>"(<7K;YH] M5Z%82=J$^!!&&N*<<^9ST6S[!Z5&T?95O-RCEU@5 9<8WS2J-2S%UGB5P/&M MG#P=$Q+-E L&08:7)"82J3E^34@3_BNEVOZKR2.FJW"$2M"/F(9 M-AIRM1:!MG&IA&!:$L;1>$[2M!'\6:PUDSY@R.S-D77.UI$.$9)>-T(^8LZ+ MD!&_'H8X2IKMHG%8!/V>7L-)P>B"RV;]N'Z&U3-L+([W1]072N0/)J<_Z3(T M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+ M.7\N?<^E[[GT/:'2MSAD6R4)RU3393>* M$IY"&V[I4_5*E=?EK[DHN#Q;Y.FOH70^+,_Y/%_GM,T+,T.WF)&Y M"M-2D&_#^>G%>!KB.=D$N7V85VWGV-'1^^?!4;"C[SR6'<>(\J(A[J&&F,_# M0X=Y>U^89Y7&4#04;6RL)"Q&MV"XU_$L%.!D8"V@!X.O40+R4E5@,5O& RN0 MHGQ,C$7H<.>77%_CT9+CVZ9EM6ZO*7<9;2)2.<)IF!-GJ\K>9;'!51W/55OR ML+YJ/;053L_^6:W(GPP13A8+$DACE!>F2J+S&5.^YRM)Q%4XOT4SMA*7&+SC MYL=Q3E.X$G:V#P(RN;LYJ7IE,6>F\M\M# DL6XA9$N)-7>W5YYNTB42%(JP# 4A M%W+C[^^3:G>,U_HL@6V$5#)DU1?*0XG!/3-R0]A4)?.NVB8+A=OB5,V[&KXF M8$O#>FZ=+2?_VU[4/;07/4;SHYG@'K.' MYA,L0Z1^P7V*BH 1JV*^NJ]/^26<.[1[\8$@F_S6VZ3VW> ,?-2K6J5D*Q$_ M2P=\'Y(&8XQ;]#1?CQ1BK::QK<;:,0QY@%CS#*%F.-^'19H:,]6+K#F-"F]! MU4#E/]O4#6CV#30,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04 M" I2[18-R"@)78$ X$0 & 'AL+W=OE>F,2 U<3..DXI MW_[& 1*V%R94HN1I_OEE//F/37/JC?9P\/#[.@"1O*\ X&??N1AGE'=6TWU5R0Y2Y&M3, M1O:H633 <6%&Q=,*SG*(T_VA?&6J6],@90[4_'W8[2[,/1'V1+?$M2_@XS9^ MC:X!0$[AYA1N)E?'*,@_@T6B%8S3OV5 .X5&N8(IWILDIC[K65"="5.OS.K_ M_M%IV7\@?/6>N1A^G@WGGSQ+LAX,KQ">#LY;^<Z/@=K3M_(. VON0^S3S]]"#CBJY]Z5[7W5;3 M1? 1J2@GPR4=V_Y X&\*[AU"X\TJY_UX_(I;= 0'-70<=[Z1 MI;BXI)=R&!#'1@>]: D.;NKO 8=F#T9[+C>B% Z7FRDN?*:EP."*5N'@7O\> M+J_%F9*OYD:EA+CFY$\,K>@>#F[Z[]%F,M%@-G_S^/0+@BO:G68#LVNGZ!\. M;O[9& Y@=GL:!1?XU+*O/V,H1>MP<,]_E#YD9;:6 NME%2+U=O/2==TV1E0T M!P?W]!^*:\T$I":*4K&WX*24"A>JFH@X16-PWZO^1C9,D M!;)*0%RV$O!H!8";\YQKF+7))7'<3XO/Q&-^"O56.O6H4#+U*476F#PM_9<+ M\IM]928D)*:*O-(P922&9T[65*'L12MP<>^>*QJ8&O2VT4*65F"%@)G@822% M[[NX1Q_21D9O_IJ*%3LYXZP0F@R\N\$WC*DP?/"$U++2SS36C M\$*8"^#\4DI]V#&K[?S'DOY_4$L#!!0 ( "E+M%B?H!OPL0( .(, - M >&PO9KEMWDOSAR+DCO9*ZW="C M<\W[)&D/1ZY8^\XT7'ND,E8QYU5;)VUC.2M;<%(R6=[<9(EB0M-BK3MUIUQ+ M#J;3;D-O:%*L*Z//EI0&@U_*%">/3&[HEDFQMV)8RY20IV!>@N%@I+'$>2I\ M0Q=@:9\"O @:L!SC**&-!6,2,H3O_;C\&3!IK5>%E#/!)0V&8MTPY[C5=UX9 M%@_&%Q 9Y=VI\0QKRTZ+Y2T].PP_/LG>V)+;.'36-/+T08I: M*Q[V_LL)BS6;_,C16/'DL\&D'+R!6TH>N77B<&GY85FSX[V;IJFO<,[+?Y#S MGZUSS36W3%Z2]J/_-U?Y+8R3\?1<'-&K SI;"5R$&_H5[E=YYD#VG9!.Z%$[ MBK+D^L4Y]>$=V_L+_"J^7U_RBG72[69P0\_R%UZ*3N7SJGNHR[CJ+'^&^VB1 MS;>PSR5TR7M>;D?5UOM!)%[P6<<'')XC=\,31S"?@,41P+ \& /,)WAA>?ZG M_:S0_00,X[:*(BO49X7Z!*\8LAT^6)ZX3^Z?^$[S/$VS#*OH=AMEL,7JEF7P M%X^&<0,/+ ]D>ENM\6[C$_+Z'& ]?6U"L)WBDXCM%*\U(/&Z@4>>Q[N-Y0$/ MK O8[$#^>!Z8J;A/FD)7,6[8"<:1/,<0F,7XC&894IT,/O'^8* \^>Q\ETWLJ.?]74_P$4$L#!!0 ( "E+M%B7 MBKL

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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.1.u2 html 1 23 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://sonnetbio.com/role/Cover Cover Cover 1 false false All Reports Book All Reports form8-k.htm sonn-20240520.xsd sonn-20240520_lab.xml sonn-20240520_pre.xml http://xbrl.sec.gov/dei/2024 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "form8-k.htm": { "nsprefix": "SONN", "nsuri": "http://sonnetbio.com/20240520", "dts": { "inline": { "local": [ "form8-k.htm" ] }, "schema": { "local": [ "sonn-20240520.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd" ] }, "labelLink": { "local": [ "sonn-20240520_lab.xml" ] }, "presentationLink": { "local": [ "sonn-20240520_pre.xml" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2024": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2024": 23 }, "report": { "R1": { "role": "http://sonnetbio.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2024-05-20", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form8-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-05-20", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form8-k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentDescription", "presentation": [ "http://sonnetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": [ "http://sonnetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AnnualInformationForm", "presentation": [ "http://sonnetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://sonnetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": [ "http://sonnetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CountryRegion", "presentation": [ "http://sonnetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://sonnetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentAccountingStandard", "presentation": [ "http://sonnetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentAnnualReport", "presentation": [ "http://sonnetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://sonnetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://sonnetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": [ "http://sonnetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodStartDate", "presentation": [ "http://sonnetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": [ "http://sonnetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentRegistrationStatement", "presentation": [ "http://sonnetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://sonnetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentShellCompanyReport", "presentation": [ "http://sonnetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": [ "http://sonnetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": [ "http://sonnetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://sonnetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": [ "http://sonnetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine2", "presentation": [ "http://sonnetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine3", "presentation": [ "http://sonnetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": [ "http://sonnetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCountry", "presentation": [ "http://sonnetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://sonnetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://sonnetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://sonnetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": [ "http://sonnetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://sonnetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://sonnetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://sonnetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityExTransitionPeriod", "presentation": [ "http://sonnetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": [ "http://sonnetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": [ "http://sonnetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://sonnetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://sonnetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPrimarySicNumber", "presentation": [ "http://sonnetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://sonnetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": [ "http://sonnetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": [ "http://sonnetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": [ "http://sonnetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://sonnetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityVoluntaryFilers", "presentation": [ "http://sonnetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://sonnetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Extension", "presentation": [ "http://sonnetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": [ "http://sonnetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "NoTradingSymbolFlag", "presentation": [ "http://sonnetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://sonnetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://sonnetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementTenderOffer", "presentation": [ "http://sonnetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": [ "http://sonnetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12gTitle", "presentation": [ "http://sonnetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": [ "http://sonnetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityReportingObligation", "presentation": [ "http://sonnetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SolicitingMaterial", "presentation": [ "http://sonnetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": [ "http://sonnetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "WrittenCommunications", "presentation": [ "http://sonnetbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14a", "Subsection": "12" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 15 0001493152-24-020551-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-24-020551-xbrl.zip M4$L#!!0 ( "E+M%B@5KWAWAH %)R * 97@Y.2TQ+FAT;>U=:U,< M1[+]3L3\AUK=6 7$G1E@T,L2J[@(D,4:(1;0;OAC37?-3)E^;5:VN-+P[;@IGNZJRLK,R3)[-:^Q^N/IZ^'6SL?S@^.,*?BO[9OSJY M.CU^N[\M?^+;;?_U_KM/1]^KRZOO3X__\F269]5KM;M35.K*IL:I,W.K+O)4 M9T/Y8*@N36EG3W C;CW_I?>]4:DNYS9[K7#I&U69+]5()W:.#WZH765GRR=O M]]]_.KOJ#CR:Z=0FR]?_:FB^UMD?C4B"D=Z]?9I-7?%F?_L=ID[CXH_S7U_V MTLX7U:\L^?&7A9W::K#QS3?CW=]Z @]9^;^-[)=YEAEH_YW-KQ:FU(6I*QLY M=9!E>9U%&.YS$>O*Q.HPL9F-=**.=*4Q5JDN/YV-=G=V=Y1VZF.>Y14/L%3X MZC!/IS;#7;>V6BB=X=_*CLZ/1J>[0Z63/)LWWYQD46FT,\IF@PT,H8YR9T;' M#H_2E7YP M>'+V[5^>[#SAW\\/CH["[[]X9KFK,@ @D%6>?'$^]W]JZ-_6^#?7.U71[]+*$E1+YF][NJCBV&6>@; Z/ 7H4?4"8K87+P "]VE:NG M/YBHPL!5KLB;#,EEQ-CGRK3[/,+3;%9C))NIRW<8&^XAQD^3"7ZJU +1!P,G MYL8D;E5G^-_%[\6T?Z>V_&B\;\]A:7#V3H1D@RU-9.P-[+0NR#HGSU6TC!(, MG,]Z 2[M!#@R2WRZYD():I7Y,4_LCW6JIVKS"@_(JM+^<__R\_G;IZ690V?T MXY9(0;?D=<7;8938U&(3S"'*%QO9:DF&K[.E;!8V_4?+?[3\7R[SX;+*KX'( M1,B8(%P):]*)4WI*YK>[,YKE2:P@LP$BBK$[DAGL<6;Z6"_*TT*7 =F5BY/3 MT>Y$50O8*9!438BQ@.<'PL,UM%'(K?M09EQ7<((T2VSN,Q3T]T4C]OA<3O\&]O!)S,BY-1D9F8K=0L_ M[XS)R+YF>5V2TZ\6,.C<49X SRQ(!;8)TR,W#:2R]_S/](&YT4FMIXE1A0\R M:O/5]F1OR\>$^$;#K&/E$!EB5=5I7CIUO_%N?0Z[/<7[G0I]?G)P= M'E]].AL.-L[^JK;5P>'A\>7E/TXNCO'+1[U4DYTA_IL\PZ^2(JO5#/D#O"5, M $]!!CM6FV<'ET<'?WL-1WFVI38ID7V:Q/^L\S>'Y#&SY=.2?Z/LV'\A _O/ MMR"*5I&WRY&K]-R(LR5'1X$_+Q@8<#8,0[)I6@=(PB*IN*Q)'.U3=UA9'F,J M[)M)'J=G!HBBBU>\&2]@^%,R?+CZ5"?)>J2+EE)#<:# MC>8*C*\@X9\"Z"O#(^M3)F8&F&$PM2FCU=;0PI+ M,SNO*9+5+%98#4>KX=3[&FI0'WB4@V1:IT1/O$.(HVLWWP/,O7O[@8#7SC!0=UY15J:E_ M= :-W"",:Y&)EH?7UI1U*LIGUYI7!0PXB&\/&Z+L+FA ^.EPZ^@K";%Z>'UP< M;HU]VL9K% PDK9/*%HD9:0<@'#?+N_GQX&A+K(8&TS&N:WWG3SC-S?W/;\\. MKW:>[SV?O'R^L[_]&?HF(Q]L0&NIX3LPXM\FM(,G+#(D\H:+R4IJ&DS1V2]X M%(L4Y8N\K,8^Y>S.8KH]T8+0.PDK#0Q+S&:E7,_7?&O("$RTP+Y6J4FGR(#]V!=YA/]_6^9U 7LF%8K?6W$ M[S$ \'.YQGZ#G\>CE\5BF>@OUO7RK[![$!!L"M6XAC] H* 8DR3YK0L,6JHI M+&:D&'ZN&ZNS?#W_0+Q>3KI)N : *&/SVI& ,'M,^X:=-1,I><0>-@X+)DT8;-#\D')C949UH1BC8?:D:-A#5%?Y;#94N\_5YHN= M/V]!T)@\,248L74L@< ZF*Z84#L6C!';YA6)?;O(4_%I4/H<-LY81_LXI8B9 M6L)D#_H)3S.4'V6RMRZ_*0U9DFGD"C 3* PS/;SR4Z+D-6 P95S,P)#A[)# M6XOP8H7] H,/]WBC$^3706T$&$CZD+TY;04 ZS)6 0]\'!^-AZL)Q.'"FIGZ M:&(V^$^SF842QR'W(]^8PUG!,X>\;*V+[')OP%#(>F 66&):@:1F3)3D] L M1T0"8Y&AT1BAP@Q5NM3)W&I1XPP3FM?T*9Q\) E"BV_,EP*VP=YN762!/&E1 M<;(TV(!#*[6E@+62RN$+DRTXL!1(&X".()FAJ>MH*0&!U]5['PY+/";=.8=/ M*,E/1G"PF7"4-'V6$_I.=<0>F%+=S?/OMB2HA&_B90;;IV^ #76FDR7SB@AS M4S889Y&(-$";O E1>Y8X1,6=G1T590N*N+@BV38QP2 M )U9EP;95_)/B7&#C=@"N582 F@;!3D:B. M_=9[:!YU71B V'\:C=1[:Y+XM3H'PGN# ?Y9T[;#C6HT"K3IT_K^^&S=XF.KM7N^#DEH)0K8R9MFT&WK6"U[< _X]Y^@96^@KM< M:LNRK^'.^UI.S(SO:!CASM"MP@(-&BC0_6WH8HU:IMB)UZ.I@8N - 7KTJL* M3V8]_5&UT+&A;3(BL9O_\Y[X?X^"/A&7Y6&.>,4&- ,3F2P&W!?:P>D2WE3[ MZG$/!G4+Q4TCPQKTOGF)0,4Y3I+F@",3M32ZI/24+)I"?8O7GV:Q=HLWBK(W M[0 0N-TBIIPU3VY\H4:A&/F>FM;P#7"I&1!:R7"!PK[& MSBDY3(=B'!%"3 Y>^ \&&\>,_3EN'"+5@O8T3XU9N2O/RET<'YY<7FVILDXH MHPP%1Q^+;4@J:#J<0S-@8#??9"-2D32]FJ$GV:2@2$E^7$O"K@)&@4Z/<9!:QGK]0"N$]XZM)0_))P.<6:)"0OK3O$XO#V#*F3 MN<9L#I0C7CS@7L-L T5!8;/R*3+CFU 4;:>'KPA719YP:E2,H5M).3@#XM) MQG+SC)9,'JL"^T BZF#Q/B.FASZ=FDHCE.+G%P"%^..50+RKL_=/=0)(]&88 MB'@_, 8ABC=JHC]Q\RU&HY'O+[=N'EY<;OGTSC6L2=(8L9_#D"A1GWD4 MS;JHR5HR$S:,:_LM7G7Z)QAZ^PVTW4,B7V/8X7V299MO>,!'UII[AIU,U),:LI,/C@-,)P;#%=@9JVS0 M8"-I\&UI)(>N[N!FY,AYKVA"G(B.J0H_)WK7-468T&M%0#L,MCO9V5'9?/NZ MXX281>WP/("&S)PRF,P372J@#HL1C("N5\T0H4(R1H3)J!0T5+RPDWM3)+]Y M&VH-'C)-95.5)LUO9+H=MXCE*=/'M/[KI?73$H]KZ"B!V.2-L$D\75D: MX')'1D$NQU+BAI_#WFK2L4ZP2TP$A^\Q^M#GQ_D4*$C]@W+!-*3'APMM2WBK M(T,1)_6&]^WW9W DGMJ#A_F8(UNL*G4HG,,A%3_*IJAXBLQ6G<.A1+: USK) M;HA8FNN*J;12;+/)L3^&M,Y5E%?._<;Q,V2_22P!LN]DV2,"J3!!R;GGH1"< M246QB70@RA3:&G&S;\!';NLR4J4% 1$:NT-$*008"&".,\T5'E M2IH?24"?,G:::H+3;H-&)T$B?D;8;B$9?6)+D(6[KB41#+''YZ=8[+RI>?BQ MF$A8";&@VDYF.61I0D,14N1@+GYJ3G'5+./E MB3M3@IE8R0OYR('2!51+436PI%P>]U.YM0C,I'HL!4DH_ /ID?W2/97O=3"M M"9I<5NVQ0'=S9+X)YM;K9^>:7UC;EF"X4PK,%%7=I&C'G#N3ZWQMPUIY=0! M$#'=\%L(*;IBV\3<"3*.U1$2]2RP8E,3R@F]OBU+FQL^WS/T3+W@X<(8J%(3 MN(7GB'V#EW4M4>*WS[*=(A428UW&3'U$%"\[JI1P\4=*VW_W0K?L+:T%PZ." M,5S&T8TSQI M&8S;O?D"JO585R1ZVNCE;A'+&!H MZ"$GB 4IAZ%!1#PXLJ2R;3 1Q5FZFD/,'5_+BNX- 7?@.WQ"3\AZRG&DGQ]*YM*@8WO-%\6&MN,14LD>G!@#H:"6ZSNE23$DCRV9"S6OD%N-%KRZ7.H#K*E+/:>!N-97(]ML M&@W8&&@OFB^4S\>LEQ8%^((9:1&JT]%JJ:P73NX&IY_:V;BYWV9#H8AXV;R% M?]2+UD6 =99BTZ2^F)$9$XMIW1J?X-+D6?4:\RPY]ZKYX!BRX1+P*L,6EVCU M!XH+/TWG3A[IW$ZV[G)EE-$!$-^UH^"3(\I25NX; I'C!0#F\5,#5LD)K3!$=]1)D=?$JL))7!)NDPZ0\B "[EZ&ZMO@><]TET6PC47TM#L M_'&E%=K!U<0R"/=PIP=Z7?.S\KW/_.4\64:Y?X!ZL:,VOSU_L;,%1&FXU:,5 MPK?4A*=E>3:2 D,$2T*&7U.S%%\SQ+HF&BK5TMC!S\D,\$'XWE/K L@<\?7S M)2X@(V*TUJB&6'(J]@"L,B8CGI\:#3VM1WO4\RQCU=NZR%W@(GPG&_(7HL:: M%@!I/^EV&PRY+8#K5G[)9G);/-=0K++':C>!EZ2E MKL(NP\^\6TOI!ZK4']DB4:3;2E$O7-F>KR6:A,_Z='%.J#]22^)@ T,DW$O. M1S^$DE5[_[W7-DO+RC!U!#1EJ)0QXZYX:7M$\%CD-9WZY9*F=8*AB,8/)1<& M9JF?*V_"B3^%<7$^.=J2:#[8X,9AF(*KIU$-40RUB=N,F&QJ2NPNL\Q!K(6V6ON,8HPTVPG".FP-8:H((F#EQ+RMMA([[ M"(>K/82.FPB''LL 2#"5YVO#;44ET) >+LJ^$%LE4"-DO);.A[)C41WFQA,P MOE8=P$$7'5O3'JGS!))OE@\5M*FE^C41-2W =F%9UO4*-JCK@7FC!^E"5V,9 MUX]G7S$=)_3X9G2?Y%)NQNQ8 M;-AS84-$#/QW-)3VY2;7ZKUN)*;V'^07% >Z'A4.=O/R$*XI] DEU-\%[_(O M">$Y)T*6Z'_\X(HOP.NIGYYO[*># MG5>("VNJGG>(Y_[YSJ9IV&?1$@\[S+4$#C[=B+AE9Q67\[F0VKX>J,MT2Z8I MB=7J>OK&&FG8:DJL^4PV*@5MJL=Z4?Y%$ R$ 8?2J?&=;ATE3BB[H2I]VSJ^ MEH5OSKZ$8"&GA)K.@JZUK&J73C[5KE>>5;XZ.U9\)$U.DU-$2?+\FJ+2+5W$ M=0^NQ7=/GQ*;T6,,N$ 1& -X-(QF?&CKS:-_O/0QR'Q=AO/GO*O@,=Q\I7!S MS[L5K6PMC]%'X;CVU.8=]B^\^D$<9>^-!P' \>:S688=QY0)!F#.1UX$P;TD MS'92@)C:69TQ%B>G(D>%QNH[R7_<'8RXN>;U!\J__6!+4J2.K)*'$%(%1J7[ M?*8H3[^':QUL;+KH_8WOTR5RE=TY!45?=U_8*EJ,%O;:N.;E&8'U]>\[\))M M?K@\D&9J/L59^!:ED+@Q*X7PL?J*A_ZD!QNWNL]U!6#-!&XW"[R'C0VOM&P[ MP3JIWBUFF-^RD)R(2N)V#_7*C36>T?)DZMT5'M]9-M\TQ5QSV^GK1P"H*9)Z M/L)S1M2!0>FTJTHDU+T$I9)\$GJ<&Q8CH8EW6[?:.44)1[1AYS1:Z"+&AP5P MD8T-OY*$%]_*S[&ZT5%$USQ&AZ_!XMQ] 1V]%YE^V>QBQ"UYXP6U1GCHB2OJR)[O':RX__D*,//9? M>]\S.9]=2I=\Y]I3RR<(Z-D7AF$U;N*JOI:,OXMNJ@5E_?PZ%'E+BI3S?3H< M)&G>^.:!YLH[TH;K+])NHZ^Y(;(A/! M813!J;>\S>7E90RFLEQ?""?0A_23LU/)&(#L:JJ+]ML6:8IY880D<-0'X.@A MKG/&@EY3T)#=\S*_)5*@>78@M(7S[I@%IP%]7(8$-\LI!-J/$%T@-#?3'A $>5#T/J*F;7]*/[3RD- MHI-+E0G?##;\5U*M6KT!:5JV^IEO(%_].)CVG2'"5KSSA6RS.Y+XK;!ZN10* M5S]ERC-\QOTGT 4?+VQUUM2O,C/G@J8_\LDO##%EZL+F;I>(/%G"1>0\^!__ M2B=_ &W5-\ZHD_2NTZ)-0]BVMN\:"TJLR.695 M37HJOFFF(^I@&FSX=VM1QJSY?5Y1)6\"88\X[#V2ZX+< ^Z]6DZF1@M#KI]J MY78V,]Q?SR_6((JG[V%_C)'UT'M9']AL'N1&OOST^>+P^/7/+DD^J,G]&Z?! MGKU1GR3K>ZU.J0_OD5+^CY&IP^$E+\DDOXNR?\%4$L#!!0 ( "E+ MM%@010R["!\ $[$ + 9F]R;3@M:RYH=&WM76MWTSJS_IY?H=/W['>W M:S7WI%?H66V:0.@E)0FPV5]8BJTDIHYE++EM^/5G1I(=.W%*6UH@4-;>T-JR M-)H9/7/16'[Q?S<3EURQ0#C<>_EWN5#ZFS#/XK;CC5[^?=AKM-M__]]![L58 M0C-HZHF7:V,I_;UB\?KZNG!=+?!@5"SO[NX6;[#-FFZT=Y/9KE(JE8O_G)WV MK#&;T+SC"4D]B\4/N8YWN;Q_O!LW'02NDVJ*5Z)!JL6%KN&N/7L@V7BKJ&^F MFLK,IG7=5$9-'<%KE?+V;73H%O$#-\O:EI%FF"'[YZA[.FLNL]O/FA9E0#TQ MY,&$2A A]E3/ERKYRE:BD[Q@5JHC^+TPXE??[&;8'8T)-^")2BUJ&+#ATFZWBG W:AB*_(A2/VX\I&*@&IH;J5[A6L!=)C); MJSNIYA8//1E,LRDV-U,/B$ N=@T74XUZG?/SN)7@GL?DP.$%BT]4LU*]4EK# MQ<6H?9 C^.>%=*3+#EX4];^Y%Q,F*<$>\NQ+Z%R]7&MP3S)/YOM3'WAMZ=]> MKDEV(XMJ!1;AJ:+N\L7_Y/.DY3#7WB,])O?).9VP/7)CW^R3]K'ZX5.I^ORO&KP\,+^ <)(_G\'1^N-C[A)#^E)O\'1]]Q,#M0+J MX;_#"?-L^%^V7#KZ-*2N8/?HJ9+HJ>F!%*8-Z"J@;MNSV<[.'>LH"4'[UBV/;S,.5@+]!J_-P OU86LMO9!>1 MXE!TAJ@A^5(]#\N'./;+M1:U9 G_5->(!Y.&L9BSEU*$M0.E"2^*J9Z_9ZQ: MNA! \#,Q(T4F+?,Y-7$YV;O &HJ"53$XXN MQI<=&V\,'18013C+-#N-]DF:-_,/QX,5LT8S8_G 2&XOD "&/Y#'5+*#&?51 M/[-[\T^!JBQY)KHS1U)R].B:85^*I:'G:'["XIIGXH11$0;LP"S"/6@2=17= M2O6/?65WKM?SLO[-Y%6;!PXP XWY06"%@^ 6&(I/*F6GD@>SN_>>^SQY&7TF M1CQF'I\XWC?&_"8_Y@?-Z#:ZG9S^/!O-TINM-+WD#>:]*,*S![E<[H5_7V3= M)ZAG>>HZ(V^/6+ \6+!/)C08.5Y>:NT_Z*('8+'XA^L[$S25'+K4N20U8(+CKV/O$W(QFH>^7"_59BR1I M21ZCIIB_$^054_2M+/L?29$TD8JZV?]9$WPDVG<4%P8'[\[;_>9QKM<_[#=[ M+XJ#@Y6=2:_9>-=M]]O-7N[P_)@T_VF\/CQ_U22-SME9N]=K=\Y7Y;3/:*SBI'N;JFN0OE\_IA;(8:!F#'Y M9,5IAEG"X>NP==(_XK7^5KD*W3TP'MQ-QH/),=<.=O(G\_%?S.P?NW(C::\: M2(!=ZC;/^[EN\Z+3[3]S[6Y2+*.OR,/&868 MD E)V!4,2P)UF]D;>V0>L7;G$.M"Y1B:.@&1#5V7_K^^6VW1QLWP7M"E,_TO MUYP;N6=#[Q-H.[;I= K4,B\-;>52%K2EB%L[.*-3\*NQPXR"EV>.;DWC=QU%K'+1H[ [1B)"=QLL4^NO/KH M]?BJ]7GWP1:K7%[,8*;'7CO Y'ZSGSMJ=_JOF]W#B^:[?KO1(Z\[I\?M\U>] M3=(^;Q3N+.X_V[%;HD5/IIZ#@_7F#BZD>"NQY$TH'+X*+K@BI:N*^]!@L!?_>I;4>_WYN0A +&B1U8 MZ"[U!>A6])-*EKZ0P?W[7XH?.M,H[3F%_T92Z6Z#7K% .A9U(U;"*LK.$)G9 M5RM_/78T. >-I10TMCV+!V ^U1YU3X+A:>B]V0:WER!EHU4?CH]]^;E9?JB! MQ.USW#J0S _X%:ZF!0M968326VE=.SAF+KT&6WL7\)3V@M3O+E.CY;&"*-58 M%+6^'4OV<04[E^'+F,_OK<75E!:W')>!N O?'Z=_?7K3-ENMED*GVY1QI_:JL\NWO<;(?;@R9NR5 M+R%B[:!2RE=VJY6M>N6.J@E_!4]O9K]+_,"Y50EDUY6I4K/G >%RS +R.0P< M83LJ@9#TZ!6+5F5B?*CH=9)F>2,QF^^$N6P\^[$@]L?H:(-/)HX0JZR.:(P5 MQ1KW-E9V(L]+:"674+O;4W-O3GR73UFPLOJ7]B+TDN*%!6377@+\C>F 5/(A MIGHN._'TB8/?(3M@IK.U]=<*:?\W<["'MATP(;WSXON@>9Q"P=@ ZH^3; 4FXG%^2AN+,$C]YV@%X(>@YCNY/VO&E9EZ-U6EDP:\&,GZ/-K+ULB)U]. MY)N3L')U\OGA$ME>*I'9\&L'%P%XS$RBIY6M95H"MP:Z_CK\\W>Q;%^6:>_[%NZX\?&7N+M7.% 5K!Z6=>NVN&;P52),\ MN=-KN*BS&T/B([8Y/G4)NV%6*)TKW"<#5Y)M/$V,L'(1S9-+!%19$8SZO)&I MKI''OC)&?D7+F17ML_W___YGIU+>WA3GJK$F!]W[:"Z#<]4*MN_2%W- M\U)).@T'YUSF#GW?!>@$H%IYF:RWP)-F04Y7C03*L68!H=ITPNH?$ETC"!8& M/63B4A%5M:72+JM3W[5\J,^AD,YP^IC\;8R9=9G#NDOJ0WP"/@C6"0[X#1DP MEU\C?_$F2H'LY$_(T'$1:AT!N"N99P/?)0?63T)74H_Q4+A3(JATQ'"JGC0/ M\ %,0>7$HCK/1/T/.'(@8NI-HWM#[L+@^!S&3 ZFUL7>TPCSJ0'D5\[;9;I8 M3^!<&V)+A4K=\1X5]9;8^ ^!(T$[<6,F]$PN5F1;S%;=^O*AO_WJZYVQIJA0GDRQ4F]WM6FU_J3U]#&_ZB6'$S PXEIP:\4W)-V($ M%B^26J6N5SLN/@=($F>Z,SL*%@2-ULQ'&G7X[/6M5J.[S?^SUW1)Q4J=4B M3;\%W,RF!49=SVL1:\HUFB]7YN F]4I)##:U4D&WS@[ZG^'F&6Y^&;@Y-G!S M$3!T)/ 8%?5N'SKC06\HU.U]9'VRH&<6 =!L8Z?;/4*.X]=KM#'XT&C;6Q&K3&Q M7"K$D[^U\QN4F]PBITKIT>444&2CSKM-)P/NKHN-9RG=&1_TREF5K3,0.+XV MGXO6)(M,.I@#0""X,K,9655COU:\\5,*0N:=W7*4ZM-V=UJN#!3V93NWK,K^ M/>IZU^]WZ<,WXU.5JO/CKAV@1VOJS'N26Y>;Y']+!:S:@M48D"OJAHSX>/[I M^+:W>Y^KBWZ",D6;50:5-2!G:Y)3&56/NTC3D#EAM,B84U(DC')1AQ MIM[!G2O@< 2!<1G(=X1[,F#XK^484P\^%G5006PV=#Q]N(O>!R[5,\[[FAWS M527KR+[M?;4/7*KG5&-''0OCX[$P6 ND\Q>50;YRQ[/#XDXQCS%[+M%M847% MM=*ZUC1ZDYO3FWD0K*6JX*.G7JF'&OJ9)8[8U[+TWT].FH']%%G&C +Y3.+N MG&!<+?&MM.ZUA[GER(7%Q1H&21H&G842MC& ''.9)0'D/*Y2;Z%@JA5,P!3* MX4=M')6.T^?UHX*IL=PIJO^U T.CXGM /MP)V)4CX#F 3NI9N,=-+?7U%Z04 MORADT\ 6ND3.7I;WJZ[3..^7Q,0"B97Q401WZ_G<*U6Y^Y"9?/]+$/ MB$]E2#)S*(DCY)."^)'GUSV 6\GRW!33D)Y]Z/Y+B'LF0(4B3CGABXRZ)9LT M1\B6ID?GH^?YT>8_'-0E=M'I+6<6&%9[72;DK'RR6/M(6&ZA-GY,CA?8C'J,]" M6/:"O.8NH@STU/:L EE'JX_O3E5*^\8)5;^5]S<@9A,A. T4_ COG^7*I#/2#HS3A4?,IT1[00$6'V@&2["L@ZM=P0@=DW?$T M"@[,&4FJ3>X5\Q#6K3%T1R8,WTN*?)PN!S^-@-\=^AMPU[,Q,G4\*U"S,XTD M"!&X9W-]*2*.V! ]PL35=29@RGI,( )@?1P]G>"D>B<-8LX M]HOQCA$><8O MB86)HD .80Y^_')#FM\8.DM)@6B; $L8^&X4H]>Q,W DV=TME)]CTI] /";B M'"_^ B6J@$H4-(RLS;':B(K1JS&Z> *1DR!R)M],1+$G>\.@DT8)D:2L-U$? M!@R?&8:!YPA0"SPO?2ZY@6H=._.SXZ=2Z[W7;$1K7:\#,::NJX*3 2,V@YA' MO;LSB)\8.BZSS3,J-%':&@8^+ >!&9@XJ-BY8\)%K78ZT>%/DKADXQF5T1%O MUQ#V$!$./L-XQ,S>=>C <76M@QJ<@N>EZ?G6]&:'K,$E".3BS\_A.TQ<15SF M+:59_4MV5BHYG\T<7RR5V<1=-N;K(XT500,, -62QQ>C '2 L0 E0 :-#CVV M4A3!Q*VQ(>AYZ?]$]V<'W9^.2GS]_"K>3\(*1PX++.U,?T4!66S@ M='94#;C MD9T-LLS9R$7.1C_CH7A,(<$@ >_'] H(XR.=S6=> #X6,&"K',$N2 .@$?FI M,&^>2#1@CA0Z0>>R,L&.773&DZ0*>PA6DQP7OD#E7 M2F X2*5.K*GE0E])[LRYB=@[7,UHN"@TO,)#F4.B\ZXST2^*2'Z#[XQ 5U)! MOIJ2(C";9]94\DM0"ZU% 32DR"+P1$,)I.2'X&K/8-:Z"-JFA=%NG?_W/[NU[7T87/C<$[A$ M5#\>)PQ3?F@P@!4QI9%/*::>'? )2T[UV93\)"]2T"&3T_3*YP(U$G/& \8\ MO<_@NE.5\677VBV4UWSI8C>1A=*8)!:"\^CA2]L:@2+/4P-0[HX 5)@UP-B$ MZ+?"&70RQ7UQ85[A3H9X8UAVGGHA/'!9"*J(2KYNM!W\.E#JH3,*<1V$,57S MZZT5(@=>JZX.W4$X 1X<8?X=VJ^W7A\>:?#=(#[0B1S;-%5,>@T*U>EL&2HP M!O?PRI%QY*57'ZY)CO%CS@Z9JK9>[Y\U-]"Y$["*O1%,*.I\Y&^5-$8R$ Z:J8N 2_#T6 M8X,/B/>Z.!\8MS$5>(N1]=[%8;>Q43 8JP02*0.^T\XQ*"!N[#?Z MI7JU7MFNE\S*W-"@%I6>*PU^6T%S75$S:N%CB1D>C0CQ1R[%[C9JB>WH6&K&(XQAE+]@1U:^ M$JVY:YK41%S3&7K82^GA&.RG' .&<#<$CK+[*URMM%/?KBR?=%6IVZ;9FA.@ M]J#N$%R>0S+;W'[3.7,]9DV>8AY@ \JEXA.NQWRB\0Y8/L*, MDSH4+;*(&,9."[E#J4P 49_8$[.>3">5ZHSLV=P"-M'I2D.6)@?S;QSFV>@; M,D0X&L&,<-C84QV 1TZ,F5]P>FIUO^*\^%FE!\)LC\$IWY/].UX+&=$IA=/ MK&VPNL#^PS+1-E_0 -PO:L)]5(I8 9*1?9Q R%#[]1YX$ H:W D'O:\0_"(D M0CKN..>2>J[PM;R/>R@$'!&8M% ]PGWN7IGH6CNZ>J1Q$'J7J,EXF*#/ 23) M ")[\ Z(!Y"",*AW92B6TDN<412'H].FO/RNN9!KJC6CW,8&X!.>2*$FIMSK MOAYUO=MLM'O]#1*$+J)P(T(9ZE%W"NYAXM@K9764D5!12+R(XS1$(D]@O&"= M1,BIM$+D[ZJ0;,C MR$C.@%9K,=)!>,_^0PLD(ULJ-00O&H[9 SPH$-+B%/" MP#-Y=) '^F)*YD!41;4&O&&7:H=+8 0;Y[[0.*.ITEXD'X IN8H2;+.Y8>M MS1S\O:-3<_WS%MZJ[V]&<;/I%KHP=5Z&;1A*^Q"<>4KJJDAK:8IEO='M;1A M%+&%[7@QKB':78 "H5D;FLA&\2%$-?%8M$[$+"^VD\ASJ@ )0AB MV(E[B-(:!=("[KO(&B7>61&R$G%2.GKMQKXHP./$[$Z!8>57>K8)3,S18/)' M6,-;RK J?VX95KJE^M#L$U5FK19?[L:$GU%!]NQ.?N=;<7=( ;5X<$T#.W_* MT1*/*(W"U5-*8T1@ *!?@#NE]*[JZ6.Q&QW"-7 M5%E/1CWEDLRJ5"K;A[>_8Y0SZ7C=NMQ<*)/'^Q $RU<4I_&/.LNTBP$YT MY4>B-"15^H-^A4JIZ$R+&H*'TN+J.]BYS$W>]#Y/:L-[UHB*,<02WC6=9C< M%PQC@2CA,E'YCKAK[>"KXDX>3',2Q(8+#0:;Z!?RN(_""3U'3C?5I@F3CDJ7 M^5R87#'\)!PT(1BB"1&B5S,,(6B8)6"!I]QG>CU#WP/< ,+Z-WQO0K*1@P/& MOG;T!M!LZ*C:23NM"=FKZ(4J[Y:ICT%>J5@)/"X873FC@MVF._@HQC0J31_M ML^EHQ-":PU0&'B\(%*(9!7Y+$45;G[7:"+,?K N\;%A'@=ZKUCQ4;JG)F#/# M!V;N>V";D)2%G?T!R($-]4B*J;X:Z3D'_6O!&.A7+J%/$SI5M6;F^V]QIEFE MA&$1S*NB*0K3JR*&BTV5@\ B-I6;54'"9E0TI[5S,ZK0,U>Q @4_&R)9="=G M[N@3NN?;^RY,;^Z:4KDK-G\Y6@ +743K=>&&7HOSA)CU,M]:C'GH+M!WC1>C M:ZJP#SBA K(9Q^*-;X^-U*:M"9555IT%$Q$!P$Q .9W51@ V"&7RQJ:*;QX\ M9R]=P:I5&_28'%9;F=X59I1,EAZOA)[^.7#$)4@3JY&4[9(*W6;P-:26Q(U6 MD[T'C;&HVC&P9*C32PB9FZD1$5FM,4K'X)XJ:8Q./76GQ':&JGA0DF' )[J: M,07!M_:7,UQ%' R(,_'=A.HNA\\"Z:DJ13TAH[_,2&!6Y6B,\R)O<3M2Q&G] M7*_9*.!^>+PC SP&Y<.N5T=]6[R<;J8]H^?LTX[:"D"H2T3XH;-RISE#C8'@G##48+^M6U:%H:R^C9 MC%^G5LD(+2YT"?#]OT2Y\.:BQL9ELG]$FF!E;%U4.KJ+I:.M&$%Z";=#56ZK M@N^5KB?]'=YS6K&CD=K@6/R@=D[:6#Z@Z^H4N'_C8Z)OW;ZL_KG;E[_A*1*_S^$V/_X,VE[[U?EA M_UVWN;H?H5SIG,2%.14J>HT\P,*6P*0C[OH:=\9I5W;HFOREK7-FNNC6)"BQ M)DOOK>!9$0.&+^:0P53M=JD$FFF 15@AOH6MNJ.A'/, B+>?**_U''L_]9', M/\AK@AG@U9=KE0>P\XG)1M#KG)\W^^2HW>F_;G8/+YKO^NU&3U'_NG-ZW#Y_ MU=LD[?/&0AI@!0[=3MGW)Q3(O!?Q"W%ER4GWMV5BZH][FC^XXO!S9B3X%&?X MWS:SZJ-.[&BZ=X_LTG>=ZG_;I&K;CWG4_Z.BBW-0%$7%E[O^N:#>)?U,SO@8 M^[\8%_ @+V<5#_S_56/R9U(C4O'D[[ULC5LQ*[<:XENY@_0?M0H'/X*Q1QIC MAPTA=8)OCX&SI2'T MQK[9)^UC]<.GTL[1)W7.A2Y_0NK48^S-3>OS^^;)]>7A6;=9?-NI]7==R<-6 MT"I^7=]IN@W#NO]W:M#V=ONXW)Z\NO;T=?FY=CNO66 M#SX'9^/QY^K[_LE'^VWM\-V_7[N3W78YE.^*C>KU25CY[+^_J0[%\5FQ?<:< MCV_\_DV=#SJ5RN3DW[?^V[-:L?7VL].@_MEETQ^+[O#BP]G7YH=_Z)N;#ZW> MN'_-M_R/'\N='2HO*B?">T7]X3_VNZ/*!SX]L;KC\IF\NFPUQ<=WH63CX^%I MIUM_P]\7G[I:(X4!]R> MXK]C.7$/_A]02P,$% @ *4NT6"U^P]LH P Y@L !$ !S;VYN+3(P M,C0P-3(P+GAS9+56VW+:,!!][TS_0?6[,9B2! +)-*1IF4*2AMPF+QUA+Z!! M2*XD \G75_*-BX$ ;7F2=\\YNROM2M3/9V.*)B DX:QAE0I%"P'SN$_8H&$] M=.TOW6:K9:'SLX\?D/[5/]DVNB) _1JZY)[=8GU^BJ[Q&&KH&S 06'%QBAXQ M#8V%7Q$* C7Y.*"@0#OB2#54*;AN#]GV#KJ/P'PN'NY:F>Y0J4#6'&3Q[(X\#X"=A)>83>43 M_G&!>[?5M\K+"8;1Z5'_=42^'W?*HZ;K?GUY>_IY/^K$(>O2&\(8 M(WT83#8L4U]2WK1(4! MGSC:H?'NYQ082GN <9"!^UCV(M'$L0260N6!VK@*LM5K '(M-'8M$;HWU]<9 M5G+&0/4(-TT9P8H5UXP6A3$P=<7%^!+Z.*0ZD]\AIJ1/P+>0PF( RG29#+ ' M[\FEO8H9X[JE]5PE%F,+ J)[-C-HDSGCFN 4[G7RR"ST3&V(8;Q.D^N+P4+$ M;UCQM @-3TJ*:V M-B3\!+*=ZV'JA?0@ZCR_;^ZG1[H+UUV07=3"C$1MLQ@=$:K.Y4$3B6P\'(JN3M"B_ A"*ZI1Z3Y)S'=@OR12W@%);+C.U\67 MF^!F$;70KD$W/ M;@Z[E.$"53"T'I[#XB/Q%#I',7DDL':>OA&,DC*AKZW,L MES:G\QXS^I8'-8''0Z;$ZSZ-L$A)/PX[C?GSO]M!I/CX$,P_@D/#'M %^>#K M6J#NQ&IZ^0=02P,$% @ *4NT6.RU_RC^"@ @(8 !4 !S;VYN+3(P M,C0P-3(P7VQA8BYX;6S-G5UOX[@5AN\+]#^P[DT+C..)LRV0[&07&4^R,#:; MI+%GMNVB6- 2XPBAR8"2$_O?EY1$6:)X)"5%2<[%C$=\#_52?$Q27\>??MQM M*'HA(DTX.Q\='WT<(<(B'B=L?3[ZNAA?+&;S^0BE&68QIIR1\Q'CHQ]_^.,? MD/SSZ4_C,;I*"(W/T!<>C>?L@7^/;O"&G*&?"","9UQ\C[YANE5;^%5"B4 S MOGFF)".RH-CQ&?K;T72Z0N/Q@'J_$19S\?5^7M7[F&7/Z=ED\OKZ>L3X"W[E MXBD]BOAF6(6+#&?;M*KMX^YC^:<(_T03]G2F_EKAE"!YO%AZMDN3\Y':;[G; MUY,C+M:3Z<>/QY-__G*]B![)!H\3IHY;1$8Z2M5BBSL^/3V=Y*5:VE+N5H+J M?9Q,M)VJ9EF:=.AK3M+D+,WM7?,(9WFW]^X&@0KUO[&6C=6F\?%T?')\M$OC MD3[X^1$4G))[\H#R9IYE^V>)4IHH$D;EMD=!'NQFJ! 3%3]A9(TS$JL=G:H= M'?]=[>C/Y>9KO")TA)12\@&VZ[115QDT<6WVCHB$QY?L?:[-:$_VY7='9/]# M ^KQSINPY!FF[S)?CW1N^X:\[X@?XMP?:3G.D_<=Z5KD_\5VUK;\YL-K/ZY4 M;;R6GQH6R2Z3$QB)M4E51<<(G.\AGQC*NJO:>=2HEZK1G(MVV]7,F->9DNAH MS5\F,4EDW=/OU(>Q^I W6_[G]QF7*X&+59H)'&6ZIKP9YR-+^<2TI)070OO" M(NII7*F81%Q.3<_9F!:'L0A_$'QCW6W9:FXI_)VNJOCBL,A= $8;,D%2OA41 M>5.OU-U"1ZETM*%2H994A(V_+D8_Y!KTFU;]Y]/D4(N#CI9+H.V&L&PI:[2T MH%GLJIMMIG0OU\N"Z&2+(;./M00IC>,.OI [CM7.KRA>6^P;Y:ZZV&I+]W&C M,(A.MCDR>[G2("7RUR S>00J0\+!YO)%K<[E,FE@8VMZ MG_"T;'?Q4XF#1 M@'9-2%K"H$"!W(&P% &:F3S$*S#_(E@,PZ6F] -+RZH=E4H6("BFMSY,E-X+ M)+.M$ W7\(P#2YW=E.TQ6]V?!71!@-)CKG77MI W0/$T UVR+,GVZGFZF^UF M182E<6V)*S8@>E[?)6"9>H@1;(XI[!=+9U;)@";32@,44!4V)T! M6)1BE*N1E'L!XTXD&RSVBR3JF2K:0K=H0$:;;)BJ@. K %TE&JTF,]\SB1+ MO)O'$M3D(2F>!^^A!-2[A:7'=I,90!P0.MT. 8)D$&I&^01ISB(NGGGM<8<9 MW\H!<#_C,;Q"Z8ER"]6@)C31Z@P)"+ A/@',&J$?BF=2$%?O\>05(%6#%^(N MXE@>J+3\YSIAY!ALOU7KEJX.NTVF+,* 2(+= ?R4R@_Z U(QZ):% LWT#4V= M^H=F.A2::=#03-\#S?*5!P+-R1N:>N(?FI.AT)P$#]UK)G)C[=B MR5]M#V>#2B_(M*U:@3G(PL.EY:T/%A6@UC,JQ"%R'4W*T8%P<"(T"QVULD64U4?U\K" MZ.*VH58/Y]]KJ?'Q15;97>C=(V?P P)MB:N>ALSIWC;+@^AQP)39Z[D,Y3I/ M5^-5AHG4/GS7RIS-[*:=:B+7!4'TKNFF-4WK]^:M(,KGG&=]LMJR\RV-[ M;A#0N>KE3INZQZVB('J_RYE)0JE%3;%C+!:<)E&2)6S]BSSY% FVM5!L &8,EG(RQ!_0,?3OZS^ MBG24X^Z_X4N!5?+8Q7ZSXA3(/F55N8*@PZ+FP"() @78ETG##4>E%!5:']FI M&F8MS3'*70%@M:6[OE$81*?;'+6^_(V^]C3D7^ZB1VF* "\DV&6NAWZ;27/X MKVN"0*##6.NDI)0BK?7Q0L)AREKW+P+6WA8!ZYY%P#K$1 AU:7K2^G% QB_$DI_ M9OR5+0A..2-Q<2W%=J>H6^_VB9D>V\V'9@!Q$#@-<0@\.J."QD\J"NFP\DJ8 M%Y*^<;IE&1;YN^3"-C(!.K?D #:;Q!BB@$BQ.P,(J<2H4/MY0;O('E$MLHK? M'0(;",D=OZ[=:=IX:]NJ#8B93H/0.]QESH_#VKB(\O2*94;4[T4D+^0+SG#I M#6PO)'?]4F67:?-M2ILV((0Z#8+O3U8Q*E4,UDQY2QDC9G*IM>8=3XD;*O>) M8UH6V[EC*DE >-A\=620$4AKO;"PV&!*/V_3A)$4GH@,E5L6K!:;+#0D ;%@ M\P6PD$N1UGIAX7)#Q%I.;S\)_IH]EOE9P;8!:K=L=%IN,F*5!L1*ES^ &1V" MBAB=4MH25'7U." MLD>"+LN?H:MG@B_J\?5+(U&D7H@H5N4LQL*&4)?8^:^.@(9;OSW24@8!4J\] M^'=(J@BD0QQ3 MSL_20Q9 $G_>WY,'(M1[!TNRRS[+'3UUG&$,B'5]]C:X.>;)7&]@$!"^U2UT MJI>B>@5HI9X1*ZM OZE*4%Z+[??+ZYNNY2>Y66^2?ZUP2N26_P)02P,$% M @ *4NT6/05 M;,SR8+=*>?1,E6927+9ZG9-61$4L$R9FEZTO MX_;5># :M2)MB$@(EX)>MH1LO?OKYY\B^W/Q2[L=#1GER7GT7L;MD9C*M]%G MDM+SZ ,55!$CU=OH*^&9VR*'C%,5#62ZX-10^T71\'GTIM/O3Z)V&U#O5RH2 MJ;X\C+;USHU9Z/-N=[E<=H1\)DNIGG0GEBFLPK$A)M/;VDY6)YN?HO@%9^+I MW/V:$$TCRTOH\Y5FERW7[J;9Y6E'JEFW?W+2Z_[SZ78F=G9]W\VU)ZI%Q-%"_;..V6W=G6;+]E ?U.3S0[UWGW;F5,3![VVF8B MK\+]URYE;;>IW>NW3WN=E4Y:)?RZ9F;L=J1=V]AA>*:BI, M[O76;M@K0E?&[D\T*2MR[8.[9IAQZLWNTHO:;M_*4MN8_5@H-STI^\)EO-<\ M=S&0!U[+_3DGK6G\H:N)-HK$IJR)DPGE>?W? MK>9 TFV@5R6)1UMC=:?V%8=]VHW:E8HCJ1*J+.NR+J+BO5@=[YH;17=!E*VH M'<\9WX9YJF3JH[,A(3T=W05EFVB&YI5M/W%]&'(RJ\9Y( 'R[&$ K72#1?0] MU;%B"\>E!NR>$LBWC\JWPEO#F,MCYX'.F.NOZXH[X5*W,3PN>(H P9]BCA1! MMT@1N!(B(_R!+J2J ;^O!/+^#9-WE37<)7%$@/;R*CT0^Q^8V/T^7P'XFV=W M?K>G%CC[G2) _'^^%OQ';I$B<$\5DXD]I2L ^R,QD/H9)G6/0U3>-R*!TMY* MP?D//NP#>TBHATS'A!<]&MIM.HR[0@Y%CI)SUMI$Q?XO)0H,?4<,18Z2AM98 M;!CX(%-JKS/!4<6OAB)'24#K3#;,_$889M;NKO_G+)W\N'&ZS_I8!66,DG3Z M3*&P+>\T".,>9H3X'BJAC%%RS9 Y%,X#ZT<1/A()77VDZQ#H(RF4-$J.&;2' M@OI>L92H]9C%]8/&L18*&R6S#!M$H?U(5J/$NF)35CP.K(?N+0)ECY)6@NRB MA& D8JD6M](]^YA+$;P?>ZR"TUS#J ML>0L9H:)V2=[A:@8X=64BF$$D9)\ +6&H:\UX]JO <2*%B4 MS*[2#M*8<+.*YT3,J'_V0K42"A@ETPN90QM[9Z"Q=_;"L1 MGGN*%W:$B/M*0,$C/D0,FT6:GV:HZS-[IN^)(9L>AOC[2D#Y(SY0#)M%FS^O M!O;$,Y/A9^8'0BAMQ*FPE=90((]3POEUIIF@.CBV' BAD!'GO%9:0X%\DU(U MLX/:!R679KY9VQF"[2D A8XXLS5H%0?^ZLNGO#,CF[>%)CW4EX)& 25= MA9K&.;?NK.0/GEKW=%#>B(EIE3&<-5/9A+-XR"4)7I?OR:!\$;/0"ELH>*^) M>%+9PL3K>R5C2MWC$[T]V@ )$; ":$@0\],7H<"Y72#3U"TFDO'3>&Y-Z[O, MY.\OM?T+WC0(EH.&!G,1)\ XTE60_K'0BR;7ZP#DY+3$N:'1M4$L! M A0#% @ *4NT6!!%#+L('P 3L0 L ( !!AL &9O M'-D4$L! A0#% @ *4NT6.RU M_RC^"@ @(8 !4 ( !CCT '-O;FXM,C R-# U,C!?;&%B M+GAM;%!+ 0(4 Q0 ( "E+M%CT'(V'50< -=7 5 " M ;]( !S;VYN+3(P,C0P-3(P7W!R92YX;6Q02P4& 4 !0 V 0 1U # end XML 17 form8-k_htm.xml IDEA: XBRL DOCUMENT 0001106838 2024-05-20 2024-05-20 iso4217:USD shares iso4217:USD shares false 0001106838 8-K 2024-05-20 SONNET BIOTHERAPEUTICS HOLDINGS, INC. DE 001-35570 20-2932652 100 Overlook Center Suite 102 Princeton NJ 08540 (609) 375-2227 false false false false Common Stock, $0.0001 par value per share SONN NASDAQ false